# CERTIFICATE

## DIRECTIVE 98/79/EC
## EC DESIGN-EXAMINATION

CeCert Sp. z o.o. hereby confirms that manufactured by

**Shenzhen Microprofit Biotech Co., Ltd.**
**Rm. 405, 406, Zone B/4F, Rm. 205, 206-1, 207, West Side of Zone B/ 2F, Haowei Building, No. 8 Langshan 2nd Road, Songpingshan, Songpingshan Community, Xili Street, Nanshan District, Shenzhen, P.R. China**

*in vitro* diagnostic medical device for self-testing

**fluorecare SARS-CoV-2 & Influenza A/B & RSV Antigen Combo Test Kit**
**catalogue numbers: MF-71-1, MF-71-2, MF-71-5**

in term of the design conforms to the requirements of Annex III section 6 to Directive 98/79/EC (as amended) implemented into Polish Law, as evidenced by the assessment conducted by CeCert Sp. z o.o.

CE 2934

Validity date: 12.05.2022 – 26.05.2025

Edition issue date: 18.05.2022

Check it

Kamil Szczurowski
Director of *in Vitro* Diagnostic Medical Device Certification Department

CeCert Sp. z o.o.
ul. Żurawia 32/34
00-515 Warszawa

www.cecert.pl
e-mail: biuro@cecert.pl

Certificate no: CeCert/092/W/E.2